COVID-19 UPDATES • 11/30/2021
Melissa L. Rayhill, MD, has co-authored an editorial that highlights new treatments for those suffering from migraine headaches.
Published August 5, 2021
Melissa L. Rayhill, MD, clinical assistant professor of neurology, highlighted the many advancements being made to help people suffering from migraine headaches in an editorial she co-authored that was published in June in the Journal of the American Medical Association.
An estimated 1 billion people worldwide suffer from migraine headaches, which can cause nausea, severe pain and sensitivity to light and sound. But despite the high incidence of the disorder, patients who have frequent headaches and typically take two medications — one for prevention and one for acute onset — often have to try several different medications before finding something that is effective.
That difficulty, and new treatments that have the potential to address both acute and preventive therapy of migraine, were also addressed in the editorial.
“The last few years have been revolutionary for headache medicine with the number of treatment advancements,” says Rayhill, who directs the adult neurology residency program. “Nevertheless, there are still far too many patients out there that haven’t found a treatment that works for them, despite the growing number of therapeutic options.”
She says many patients are not offered effective, migraine-specific therapy, even though there are many available.
“In addition, many patients never even seek out care at all because of misconceptions about why they may have headache in the first place,” says Rayhill, who treats patients at UBMD Neurology.
But things are rapidly changing in the treatment of migraine.
“There are so many good, migraine-specific acute treatment options now,” she says. “For some patients, the quest to find something that works can take months or longer. Many will find a safe and effective acute treatment for their migraine headaches after just one visit to their physician’s office, though typically it may take a couple of medication trials over a few weeks to find a good fit.”
While the traditional approach to chronic migraine treatment has been to prescribe two medications — one that acts as a prophylactic and another that acts on acute episodes — that approach is changing.
“In our editorial, we highlighted some recent studies that show some new treatments are blurring the lines between acute and preventive migraine treatment,” Rayhill says. “One acute therapy was recently shown to be effective in headache prevention when orally dosed every other day, and one intravenous preventive therapy was also shown to be effective in the acute treatment of headache. This new approach totally upends our prior conceptions about migraine treatment.”
In the editorial, Rayhill and co-author Rebecca C. Burch, MD, assistant professor of neurology at Brigham and Women’s Hospital and Harvard Medical School, discussed a recent study on eptinezumab, which was published in the same issue.
“Eptinezumab is an intravenous therapy approved for preventive treatment that is given in an infusion center or delivered at home by a visiting nurse,” Rayhill says. “The study suggests it may be helpful for acute therapy as well, though logistical and cost considerations may preclude utilizing this approach in practice more routinely now.”
She adds that the other subcutaneously delivered medications in the same class (monoclonal antibodies targeted against calcitonin gene-related peptide, CGRP, a migraine signaling molecule) have not been explicitly studied for acute therapy in large trials, and that in clinical practice these other medications have usually taken weeks and even months to see an effect in most patients.
Another treatment that she says may be blurring the lines between acute and preventive therapy for migraine is rimegepant, a small molecule, direct CGRP antagonist.
“Rimegepant was recently approved by the Food and Drug Administration for the preventive treatment of migraine after initially being approved for acute migraine treatment in early 2020,” Rayhill says, adding that most acute therapies for migraine are judged by whether they relieve pain and associated symptoms within two hours of taking the medication. In a recent study, the drug was also effective in reducing headache frequency when dosed every other day.
While finding the right migraine medication usually takes some time, Rayhill notes the outlook for patients is definitely improving.
“I have seen some dramatic responses to many of our existing conventional medications for both acute and preventive therapy,” Rayhill says. “The newer CGRP monoclonal antibody therapies (the intravenous therapy, eptinezumab, and the other three subcutaneously delivered medications in the class) and the CGRP small molecule antagonists (the oral medications rimegepant and ubrogepant) have produced similar dramatic responses in my clinical practice,” Rayhill says.
“It’s important to note that these responses are very individualized, and sadly, some do not respond to any of the above therapies. However, I think where both classes of CGRP therapies shine is in their improved tolerability — in other words, the decrease in reported side effects in comparison to other conventional therapies,” she adds.
Unfortunately, she cautions, cost remains a huge barrier for many in accessing the CGRP therapies, and insurers are often reluctant to cover them.
“Migraine is a disabling neurological condition that patients inherit, and there is currently no cure,” Rayhill says. “But because of the number of effective treatments now, the future is brighter than ever for patients who suffer with migraine. Amazingly, there are even more migraine therapies in the pipeline.”
“Patients with migraine should be able to expect that the clinicians who care for them are familiar with and comfortable using multiple acute treatment options,” she concludes. “Help is within reach.”
The Jacobs School is part of the University at Buffalo Academic Health Center, one of the most comprehensive academic health centers in the nation.